Chairman Age 69
Appointed to the Board 1 March 2005: Chairman of the Nomination Committee. Member of the Audit and People & Culture Committees.
Background: Global executive and leadership experience in capital markets and derivatives, and a background in venture capital activities. Former President of NationsBank-CRT, Chicago and Managing Director of Hong Kong Bank Limited, London.
Other boards: Chairman, ASX Limited and Director, Servcorp Limited. Non-executive Chairman, QBiotics and member of the Macquarie University Faculty of Business and Economics Advisory Board.
Former directorships: Chairman, Snowy Hydro Limited and SFE Corporation Limited. Director, St George Bank Limited, Exco Resources NL, DCA Group Limited and MIA Group Limited.
Qualifications: BA (Hons), FAICD, CA
CEO & President Age 51
Appointed to the Board 14 November 2017 and as CEO & President 3 January 2018: Member of the Medical Science and Technology & Innovation Committees.
Background: Joined Cochlear in 2000 and has a wealth of experience across the Company in roles including Chief Operating Officer, SVP, Manufacturing and Logistics and President, Asia Pacific. Prior to joining Cochlear, worked for Boral and Boston Consulting Group. Appointed as President of Cochlear on 31 July 2017 and became CEO & President on 3 January 2018.
Qualifications:BE (Hons), MBA
Non-executive Director Age 54
Appointed to the Board 2 August 2010: Chairman of the Audit Committee. Member of the People & Culture, Nomination and Technology & Innovation Committees.
Background: Extensive career in investment banking with senior roles in strategic analysis and corporate advice. Former Vice President of Deutsche Bank AG.
Other boards: Director, Santos Limited, ASX Limited and National Portrait Gallery. Member of the George Institute for Global Health Board and Australian Government Takeovers Panel. Chairman, Advance (Global Australian Network).
Former directorships: Director, Insurance Australia Group Limited. National director of the Australian Institute of Company Directors. Member of The Salvation Army Advisory Board. Chair of Macquarie Specialised Asset Management. Director, ANZ Investment Bank and Associate Director, HSBC London.
Qualifications: BCom, FAICD
Prof Edward Byrne, AC
Non-executive Director Age 66
Retired on 16th October 2018
Appointed to the Board 1 July 2002: Member of the Medical Science, Nomination and Technology & Innovation Committees.
Background: A neuroscientist with extensive experience in clinical neurology and basic neurological research. Vice Chancellor of Monash University (2009-2014). Former Executive Dean of the Faculty of Biomedical Sciences, Vice Provost and Head of the Medical School at University College London. Former Dean of Faculty of Medicine, Nursing and Health Sciences at Monash University, Melbourne (2003-2006).
Other boards: President and Principal, King's College London. Chairman, King's Health Partners, and Director, Russell Group UK.
Former directorships: Deputy Chairman, Group of Eight Vice Chancellors, Australia and Chairman, Global Foundation. Director, Bupa Group Board, London and Bupa Australia Pty Ltd.
Qualifications: DSc, MD, MBA, FRCP, FRACP, FTSE
Non-executive Director Age 70
Appointed to the Board 1 February 2007: Chairman of the Technology & Innovation Committee. Member of the Audit, Medical Science and Nomination Committees.
Background: Extensive experience in the life sciences industry. Former director of Principals Cornerstone Management Pty Limited. Former Managing Director of Memtec Limited and President Asia for Pall Corporation.
Other boards: Chairman, SpeeDx Pty Ltd and Director, Vaxxas and QBiotics.
Former directorships: Executive Chairman, Universal Biosensors.
Qualifications: BSc (Hons), MBA, FAICD
Non-executive Director Age 65
Appointed to the Board 1 August 2005: Member of the Audit, Medical Science, Nomination and Technology & Innovation Committees.
Background: Executive experience in global general management of healthcare products and medical devices. Former worldwide President of Cordis Cardiology (a Johnson & Johnson company) and President of Baxter's Cardiovascular Group.
Other boards: Chairman, Atcor Medical and Director, Mesoblast Limited, Fisher & Paykel Healthcare Limited and NIB Holdings Ltd. Chairman of Endoluminal Sciences.
Qualifications: BE Civil, MBA
Glen Boreham, AM
Non-executive Director Age 54
Appointed to the Board 1 January 2015: Chairman of the People & Culture Committee. Member of the Audit, Nomination and Technology & Innovation Committees.
Background: Led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. Former Managing Director of IBM Australia and New Zealand.
Other boards: Director, Southern Cross Media Group and Link Group. Chairman, Advisory Board IXUP.
Former directorships: Director of Data#3. Chairman of Screen Australia, Advance (Global Australian Network), Business School and Industry Advisory Board for the University of Technology, Sydney.
Qualifications: BEc, FAICD
Non-executive Director Age 51
Appointed to the Board 1 January 2015: Member of the Audit, Nomination, People & Culture and Technology & Innovation Committees.
Background: Extensive experience leading technology-enabled businesses across e-commerce, media and financial services. Former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand.
Other boards: Director, Westpac Banking Corporation and Ramsay Health Care, Senior Advisor to McKinsey & Company, member of Investment Committee, Main Sequence Ventures, Director of SCEGGS Darlinghurst Limited.
Former directorships: Director of Insurance Australia Group Limited, Social Ventures Australia and kikki.K Holdings Pty Ltd. Chairman of ninemsn, Allure Media and Downstream Media.
Qualifications: BA, MBA, GAICD
Prof. Bruce Robinson, AM
Non-executive Director Age 62
Appointed to the Board 13 December 2016: Chairman of Medical Science Committee. Member of the Nomination, People & Culture and Technology & Innovation Committees.
Background: Over 20 years' leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Former Dean, The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.
Other boards: Chairman, National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce. Director, MaynePharma, QBiotics and Digital Health Agency CRC Pty Limited.
Former directorships: Director of Firefly.
Qualifications: MD, MSc, FRACP, FAAHMS, FAICD
Non-executive Director Age 53
Appointed to the Board effective 1 December 2018: Member of the Nomination, Medical Science and Technology & Innovation Committees.
Background: Extensive experience in the pharmaceutical industry with global experience in building relationships with professionals within the healthcare industry. Previously Global President, Pharmaceuticals at GlaxoSmithKline.
Other boards: Director, CSL Limited and Immunocore Limited.
Former directorships: Director, ViiV Healthcare Limited, Aspen Healthcare and the Duke/National University of Singapore Medical School.
Qualifications: BSc (Hons)